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ABSTRACT 
Objectives: To evaluate the persistence and adherence on urate lowering treatment 
(ULT) in the primary care five years after an initial nurse-led treatment of gout.   
Methods: 100 gout patients initiated on up-titrated ULT between March-July 2010, 
last study visit March-July 2011, were sent a questionnaire that elicited information on 
current ULT, reasons for discontinuation of ULT if applicable, medication adherence, 
and generic and disease specific quality of life measures in 2015. They were invited 
for one visit at which height and weight were measured and blood was collected for 
serum uric acid (SUA) measurement.  
Results: Seventy-five patients, mean (standard deviation (SD)) age and disease 
duration 68.13 (10.07) and 19.44 (13) years respectively returned completed 
questionnaires. The five-year persistence (95% (confidence interval (CI)) on ULT was 
90.7 (81.4-91.6) %, and 85.3% responders self-reported taking ULT on ≥6days/week. 
Of the 65 patients who attended for the study visit, the mean (SD) SUA was 292.8 
(97.2) µmol/L. 
Conclusion: An initial treatment that includes individualised patient education and 
involvement in treatment decisions, results in excellent adherence and persistence on 
ULT >4 years after the responsibility of treatment is taken over by the patients’ GP, 
suggesting that this model of gout management should be adopted widely. 
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Key messages: 
 Excellent long-term persistence and adherence on urate lowering treatment 
can be achieved if patients are initially educated about gout and its’ treatment. 
 The benefits of such an individualised education persists even after the 
responsibility of gout treatment is taken over by the patients' own GP.     
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Introduction: Gout is the commonest inflammatory arthritis with a prevalence of 2.5% 
(1). Although curable, its management is suboptimal as evidenced by low urate 
lowering treatment (ULT) initiation rates even in people who consult their GP for gout 
and fulfil the recommended criteria for  ULT [1, 2]. Moreover, the persistence and 
adherence on ULT is generally poor [1, 3, 4]. For example, half of all men and women 
discontinued ULT by 358 and 379 days in a community based study, while another 
study reported the 12-month persistence on ULT to be even lower at 22.6% [4, 5]. 
Apart from this, adherence to ULT ranges from 10-46%; and is lower than medication 
adherence in other chronic illnesses including rheumatoid arthritis [1, 3, 4, 6, 7]. In the 
UK, only 34-38% gout patients get initiated on ULT, and of these, only 39% are 
adherent to ULT at 12 months [1, 2].  
A proof-of-concept study from Nottingham, UK demonstrated that a predominantly 
nurse-led treatment package consisting of individually tailored patient information 
regarding gout and its management, and initiation and upward dose titration of ULT 
as per the British Society for Rheumatology (BSR) recommendations resulted in 92% 
gout patients persisting on ULT at 1 year [8]. However, whether these patients would 
persist on ULT in a real world setting, in the long-term, once the responsibility of 
prescribing ULT is taken over by the patients’ own doctor at the end of the 12-month 
study period is not known.  
Thus, the overall aim of this study was to explore the effects of an initial nurse-led gout 
treatment on ULT continuation in the long-term. The specific objectives were to [1] 
examine the persistence and adherence on ULT, [2] calculate the proportion of 
patients who meet the British Society for Rheumatology and European League Against 
Rheumatism treatment target for serum uric acid (SUA) at 5 years [9].  
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Methods:  
Study design Cross-sectional study 
Setting Primary care 
Case definition Crystal-proven gout patients previously participated in the proof-of-
concept study, recruited March to July 2010, and last study visit July 2011 [8].   
Recruitment 100 of the 106 gout cases (5 dead, 1 moved out of the area) were sent 
a postal questionnaire in September 2015. The questionnaire elicited information 
about demographic characteristics, current ULT, reason(s) for ULT discontinuation 
(if applicable), self-reported adherence to ULT, and quality of life assessed by the 
Short Form 36 version 2 (SF-36v2) and the Gout Impact Scale (GIS) of the Gout 
Assessment Questionnaire version 2 (GAQv2) [10, 11]. Responders were invited to 
attend for a hospital visit at which height, weight, and blood pressure were 
measured; and blood was collected for SUA measurement. Data on SUA, serum 
creatinine measurements requested by GPs between July 2011 and September 
2015 were obtained from Clinical Chemistry Department, Nottingham University 
Hospitals NHS Trust.   
The postcode of each study participant was used to obtain their Index of Multiple 
Deprivation (IMD), a composite measure of socioeconomic and healthcare 
deprivation, from the Department for Communities and Local Government, England 
(http://imd-by-postcode.opendatacommunities.org). The IMD ranks each postcode 
(n = 32,844) in England according to their relative deprivation, with lower ranks being 
the most deprived. This study was approved by the Medical School Ethics 
Committee, University of Nottingham, UK, Ref: B18062015 SoM ROD. 
Statistical Analysis N(%) and mean (standard deviation (SD)) were used for 
descriptive statistics. Persistence and adherence rates and their 95% confidence 
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intervals (95% CIs) were calculated. Independent sample T-test and chi-square test 
were used to compare the baseline disease and demographic characteristics of 
questionnaire responders and non-responders. The SF-36v2 scores were 
standardised using population norms generated from a large UK community sample 
[11].  Scores of each domain of SF-36v2 at baseline and five year follow up were 
compared using paired T-test. Odds ratio (OR) and 95%CI were used to examine 
associations. Binary logistic regression was used to calculate the OR. All statistical 
analyses were carried out using STATA. p≤0.05 was statistically significant.  
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Results: 75 of the 100 questionnaires were returned and 65 patients attended for the 
study visit. The mean (SD) age, disease duration, and BMI were 68.13 (10.07) years, 
19.44 (13) years, and 31.12(4.51) kg/m2 respectively. 12% responders were women, 
and 14.7% had tophaceous gout. Questionnaire responders were older than non-
responders at the baseline visit in 2010 (Table 1). However, this was not statistically 
significant and other disease and demographic characteristics, including SF-36 scores 
and IMD were comparable between the two groups (Table 1).  
Sixty-eight of the 75 responders were on ULT at the time of follow-up questionnaire 
survey, giving a persistence (95% CI) of 90.7(81.4-91.6)%.  Reasons for discontinuing 
ULT were: felt to be no longer required (3); fed-up with taking ULT (2); temporary 
discontinuation for unrelated reasons (1); and unclear (1). Five-year persistence was 
comparable in those on allopurinol (93.1%), febuxostat (81.8%), and benzbromarone 
(100%) (p=0.47). The dose of ULT was reduced in 11 participants (Allopurinol 400 
mg/day to 300 mg/day (n=9) and 500 mg/day to 400mg/day (n=1), Febuxostat 
120mg/day to 80 mg/day (n=1)), remained the same in 52 participants, and was 
increased in three participants. Two participants were commenced on a different ULT. 
A median of 1 (inter-quartile range 0-3) SUA measurements, and 4 (2-7) serum 
creatinine measurements were requested by the GPs between the end of the proof of 
concept study and September 2015, and only 37.5% patients had ≥2 SUA 
measurements during this period. 
85.3 (74.4 - 92.0)% of responders self-reported taking ULT on ≥6 days in an average 
week (Figure 1a). The mean (SD) SUA at the five year visit was 292.8 (97.2) µmol/L. 
The SUA was significantly lower in those on ULT than in those not on ULT (mean (SD) 
SUA 269.4 (50.4) µmol/L vs. 577.2 (63.6) µmol/L, p <0.001). Of the patients for whom 
the five-year SUA levels were available, 86.4% (75.5-92.9) had SUA ≤360 µmol/L and 
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69.7% had SUA ≤300 µmol/L. Those who self-reported forgetting ULT on ≥2 
days/week were significantly less likely have SUA ≤300 µmol/L (OR (95%CI) 0.19 
(0.04-0.84), p=0.029) (Figure 1b).   
The bodily pain domain score of SF-36v2 improved over five years, with mean (SD) 
baseline and five year scores of 42.55 (10.47) and 46.01 (11.32) respectively, a mean 
(95% CI) improvement of 3.46 (0.69-6.23), p=0.015. There were no statistically 
significant differences in the other SF-36v2 domain scores over five years (data not 
shown). Similarly, study participants had excellent scores on each of the five GIS 
domains, and in the overall GIS score. The mean (95% CI) gout concern overall, gout 
medication side effects, unmet gout treatment need, well-being during attack, and gout 
concern during attack were 34.88 (28.51-41.25), 37.84 (32.15-43.53), 22.30 (17.98-
26.62), 40.47 (34.75-46.19), 32.42 (27.34-37.47).   
  
  
9 
 
Discussion: This study examined the effects of a one-year initial nurse led treatment 
of gout on long-term persistence and adherence to ULT after the responsibility for 
prescribing ULT was handed-over to the patients’ own doctor. It reports that >90% 
patients persisted on ULT at five years with excellent adherence, and that >86% 
patients met the EULAR treatment target for SUA at five years. These findings suggest 
that a personalized interactive education about gout, and full involvement of patients 
in management decisions results in improved long-term persistence on ULT even after 
the responsibility of prescribing ULT is handed over to the patients’ own GP. This 
concurs with the findings of a systematic review which concluded that patient 
education improves medication adherence [12].  As reported previously, three of the 
six patients who discontinued ULT did so because they felt that long-term ULT was no 
longer necessary [13, 14]. These findings suggest that the need for long-term ULT 
should be reinforced periodically.  
In a cross sectional study from New Zealand, patients’ determination to maintain a 
normal SUA was the only psychological determinant of treatment success [15]. It is 
possible that the individualized patient education during the proof-of-concept study 
increased their commitment to reduce the SUA to below treatment target, and that 
progressive reductions in SUA during treat to target ULT provided the requisite positive 
feedback to maintain this. Thus, the key components that resulted in excellent five 
year persistence on ULT are an experienced rheumatologist with an interest and 
expertise in gout (MD) fully assessing the patient and providing initial explanations 
concerning gout, its possible effects, and available treatment options; nurse led 
disease monitoring and ULT dose escalation and reinforcement of patient education 
over the first year; and subsequent continued prescription of ULT by the GP. Although 
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not directly measured, it is likely that the excellent adherence to ULT is at least in part 
due to ongoing follow-up and encouragement to adhere to ULT by the GP. 
In keeping with the findings of a previous study, we found that poor adherence to ULT 
associated with high SUA [16]. This study also shows that long-term ULT improves 
bodily pain in gout. The magnitude of improvement in our study is smaller than that 
reported previously, in studies undertaken predominantly in patients from secondary 
care [17], and this may be due to participants in the other studies having more severe 
disease, resulting in a greater improvement in quality of life with ULT. Similarly, the 
scores on gout concern overall, unmet gout treatment need, and gout concern during 
an attack domains of GIS in this well treated gout cohort are 25.9% to 44.7%, 20.9% 
to 41.6%, and 35.5% to 40.8% lower than that observed in other gout cohorts, 
providing further evidence of long-term beneficial effects from an initial nurse-led 
treatment of gout [18-20]. Smaller differences were present in gout medication side 
effects (13.3% to 21.7%), and well-being during attack (14.2% to 27.4%) domains (18-
20). (Figure S1)   
There are several strengths of this study, namely, a very high response rate to the 
questionnaire, and long follow up period. However, there are several caveats to this 
study. Firstly, we do not have information about persistence and adherence on ULT in 
those who did not respond to the follow-up questionnaire. Additionally, the 
questionnaire non-responders were 4.6 years younger than responders.  Since 
persistence on ULT is lower in the younger age group, it is possible that the overall 
long-term adherence and persistence on ULT in the proof-of-concept study 
participants is lower than that estimated in this study. Similarly, non-responders had 
slightly worse disease at baseline, which could relate to socio-economic deprivation, 
which associates with reduced medication adherence. However, responders and non-
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responders had similar socio-economic deprivation scores (Table 1). Nevertheless, 
even if all non-responders are assumed to be not taking ULT, the five year persistence 
on ULT would be 68%. Even this is much better than other reports of long-term 
persistence on ULT. Unfortunately we did not collect information on GIS during the 
proof-of-concept study in 2010-2011, and are unable to measure any long-term 
improvements in disease specific quality of life from the initial nurse-led package of 
care. Due to the small sample size, and high persistence and adherence rates, we did 
not perform multivariate analysis to identify the disease and demographic predictors 
of non-persistence or non-adherence to ULT, as any such analysis would be prone to 
type II error. Additionally, we do not have data on the number of times a patient was 
seen by their GP for gout between the final study visit in 2011 and the questionnaire 
survey in 2015. These data are likely to be inaccurate when captured retrospectively 
in a questionnaire survey after four years because a review of gout would have been 
part of broader periodic medical review, and the patient may not remember being 
asked by their GP about gout several years later.  
In conclusion, this study demonstrates that an initial package of care that includes 
individualised education, patient involvement in management decisions and a treat-to-
target approach to ULT results in the best long-term ULT adherence and persistence 
reported so far. Such treatment may be initiated by a suitably trained nurse or by any 
other allied healthcare professional like a community pharmacist. Further research is 
required to find out if persistence and adherence to long-term ULT is due to retained 
knowledge of gout and its treatment, and if such treatment improves renal function 
and reduces the risk of cardiovascular disease.  
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Table 1 Disease and demographic characteristics at the beginning of the proof-of-
concept study (2010) according to response to follow-up questionnaire in 2015 
 
Questionnaires returned 
(n=75) 
No response or not 
mailed (n=31) 
p 
Age, years mean (SD1) 62.2 (10.1) 57.6 (13.2) 0.06 
Sex, % female 12% 9.7% 0.73 
BMI2, kg/m2
 
mean (SD) 31.1 (4.5) 30.2 (5.2) 0.34 
Age at first attack, years 
mean (SD) 
48.7 (15) 43.5 (16.7) 0.12 
Number of attacks in 12 months, 
mean (SD) 
3.8 (3.6) 4.3 (3.0) 0.52 
Tophi, % present 14.7% 19.4% 0.55 
Serum uric acid, µmol/L mean (SD) 456.6 (11.4) 453.6 (18.6) 0.88 
SF-36v2 domain scores    
Physical function 41.4 (14.1) 40.8 (15.3) 0.80 
Role physical 44.0 (12.9) 43.7 (13.0) 0.93 
Bodily pain  42.5 (10.5) 44.4 (13.2) 0.44 
General health  44.4 (11.1) 43.6 (12.1) 0.74 
Vitality  51.4 (10.6) 47.4 (12.5) 0.10 
Social functioning   49.3 (10.8) 48.7 (12.0) 0.81 
Role emotional  49.1 (11.7) 46.2 (12.4) 0.25 
Mental health 53.3 (9.5) 49.5 (13.1) 0.10 
Index of multiple deprivation rank, 
median decile (inter quartile range) 
6 (3-8) 5 (3-7) 0.33 
1SD standard deviation 2BMI body mass index 
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Figure 1 (a) Self-reported adherence to urate lowering treatment in those currently 
on urate lowering treatment (left panel); (b) Proportion of patients meeting the 
treatment targets for serum uric acid according to self-reported adherence to urate 
lowering treatment (right panel) 
 
 
 
Figure S1 Gout Impact Scale domain scores in this study, and in other cohorts (18-
20)  
 
